secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2023-10-20T23:59:59+00:00
Accession:  0001104659-23-110537
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics receives Nasdaq bid price deficiency notice; 180 days to cure
--------------------------------------------------------------------------------

- Stock closed below $1.00 for 32 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- 180-day compliance period ends April 15, 2024; must close at $1.00 for 10 consecutive business days.
- If not cured, company may be eligible for another 180-day period if it meets other listing standards.
- Company intends to monitor bid price and evaluate options, including reverse stock split.
- Failure to regain compliance could lead to delisting from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923110537/0001104659-23-110537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923110537/tm2328605d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-110537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer